Corient Private Wealth LLC Lowers Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Corient Private Wealth LLC trimmed its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 9.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,855 shares of the biotechnology company’s stock after selling 2,000 shares during the quarter. Corient Private Wealth LLC’s holdings in Aurinia Pharmaceuticals were worth $178,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of AUPH. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth approximately $25,000. Blue Trust Inc. grew its stake in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock worth $57,000 after buying an additional 6,174 shares during the period. FMR LLC increased its position in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,919 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $108,000. Finally, Bailard Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $128,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 27th.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, COO Matthew Maxwell Donley sold 65,902 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $527,216.00. Following the transaction, the chief operating officer now owns 739,456 shares in the company, valued at $5,915,648. The trade was a 8.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Greg Keenan sold 8,305 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the transaction, the insider now directly owns 153,484 shares of the company’s stock, valued at approximately $1,263,173.32. The trade was a 5.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock valued at $2,753,094 over the last 90 days. 4.30% of the stock is owned by corporate insiders.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ:AUPH opened at $8.05 on Wednesday. The business’s 50-day simple moving average is $8.10 and its 200 day simple moving average is $8.07. The company has a market cap of $1.11 billion, a P/E ratio of -53.66 and a beta of 1.26. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals Inc. has a one year low of $4.71 and a one year high of $10.67.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.